Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine and Remimazolam for Postoperative Sleep Disturbance in Gastroenteroscopy
NCT06108830Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine and remimazolam in Postoperative sleep disturbance (PSD) and anxiety disorder (4 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Sleep disturbance and anxiety after surgery. Started Dec 2023; status: recruiting.
02
Drugs
esketamineremimazolam
03
Conditions
Postoperative sleep disturbance (PSD)anxiety disorder
Beyond the preview
Go deeper on NCT06108830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108830.